CARBIDOPA, LEVODOPA, AND ENTACAPONE (Carbidopa, Levodopa, and Entacapone) Nursing Considerations

What is the generic name?

CARBIDOPA, LEVODOPA, AND ENTACAPONE

What is the Trade Name for CARBIDOPA, LEVODOPA, AND ENTACAPONE?

Carbidopa, Levodopa, and Entacapone

What are the Indications for CARBIDOPA, LEVODOPA, AND ENTACAPONE?

• 1 INDICATIONS AND USAGE Carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-O-methyltransferase-COMT inhibitor) are indicated for the treatment of Parkinson’s disease. Carbidopa, levodopa and entacapone tablets can be used: ‚Ä¢ To substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. ‚Ä¢ To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose ‚Äúwearing-off‚Äù and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias. Carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa (aromatic amino acid), carbidopa (aromatic amino acid decarboxylation inhibitor), and entacapone (catechol-O-methyltransferase (COMT) inhibitor) are indicated for the treatment of Parkinson’s disease. Carbidopa, levodopa and entacapone tablets are to be used: ‚Ä¢ To substitute (with equivalent strengths of each of the three components) for carbidopa/levodopa and entacapone previously administered as individual products ( 1 ) ‚Ä¢ To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose ‚Äúwearing-off‚Äù and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias ( 1 )

References: https://open.fda.gov/